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http://Contents lists available at ScienceDirectEditorialNew classiﬁcation of membranoproliferative glomerulonephritis:
a good start but a long way to goAs with other primary glomerulonephritis, pathologic diag-
nosis of membranoproliferative glomerulonephritis (MPGN) is
based on characteristic histologic ﬁndings such as mesangial
and endocapillary proliferation accompanied by thickening of
the glomerular basement membrane (GBM) frequently
demonstrating “double contour” due to the interposition of
mesangium and inﬁltration of mononuclear cells into the
subendothelial region, deposition of immune complex and/or
complement, and the formation of new GBM material.
MPGN has traditionally been classiﬁed according to the
locations of electron dense deposits, where MPGN I is character-
ized by mesangial and subendothelial deposits, and MPGN III by
the presence of subepithelial deposits in addition to mesangial
and subendothelial deposits. Burkholder subtype of MPGN III
has prominent subepithelial deposits which correspond
to spikes of GBM in light microscopy [1] whereas the
Strife and Andes subtype of MPGN III is characterized by
subendothelial deposits extending into subepithelial regions
across the GBM causing disruption and lamination of lamina
densa of GBM [2].
MPGN II, which is diagnosed by very unique electron
dense transformations of GBM due to extensive deposition
of complement 3 (C3) and other alternative complement
pathway (AP) proteins, was considered a separate entity
from MPGN mainly because typical microscopic features of
MPGN were observed only in a minority of cases and
consequently the term was appropriately replaced by “dense
deposit disease (DDD)” [3].
Intense staining of the glomerular capillary walls for C3 is
the rule in MPGN, and the activation of complement pathways
—irrespective of classical or alternative—plays a major role in
pathogenesis of MPGN via deposition of complement proteins
followed by activation of mesangial and endothelial cells and
chemoattraction of leukocytes with resultant damages to
capillary walls from released protease and cytokines [4].
One issue related to this important role of complement
pathways in MPGN is the question “what causes complement
activation in patients with MPGN?” The simultaneous presence
of both immunoglobulin (Ig) and complement in immunoﬂuor-
escence microscopy (IF) suggests that antigen–antibody immune
complex (IC) mediates the activation of classical complement
pathways (CP). The presence of early complement components132/$ - see front matter & 2014. The Korean Society of Nephrology. Pub
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
dx.doi.org/10.1016/j.krcp.2014.10.005such as C1q and C4 in addition to C3 in IF also supports this
notion. The diagnostic approach in these patients should
include the search for the presence of chronic infections
including hepatitis C virus and hepatitis B virus, autoimmune
diseases such as SLE, and paraproteinemia due to monoclonal
gammopathy, all of which are the major causes of IC formation
causing MPGN.
The ﬁnding of isolated C3 staining without concomitant Igs
in IF together with electron dense deposits in subendothelial
and mesangial regions in patients with MPGN was called C3
glomerulonephritis (C3GN) [5], suggestive of the essential role
of AP activation in the pathogenesis of glomerular lesions as
opposed to Ig-mediated CP activation. C3GN is practically
differentiated from DDD by the absence of electron dense
transformation of GBM, although both diseases have isolated
C3 staining in common. Consequently, diagnostic approaches
in DDD and C3GN should focus on genetic or acquired defects
inducing uncontrolled activation of AP.
AP, which is constitutively active albeit low grade in the
normal state, is tightly regulated by multiple inhibiting proteins.
Fluid phase regulators of AP include complement factor H (CFH)
and complement factor I (CFI). Complement factor H related
proteins (CFHRP) 1–5 have recently been reported to competi-
tively inhibit CFH in a process termed CFH deregulation.
Cell bound and surface regulators include decay accelerating
factors (DAF: CD55), membrane cofactor protein (CD46), and
complement receptor 1. Vitronectin and clusterin act as ﬂuid
phase regulators of terminal complement complex [6].
Genetic defects disturbing AP regulation such as mutations
in CFH, CFI,CD46, and CFHRP [7–10] and gain of function
mutations in factor B and C3 [11] have been observed in
DDD and/or C3GN suggesting AP activation as a main patho-
genic mechanism in both DDD and GNC3. Moreover, acquired
autoantibody C3 convertase, namely nephritic factor (C3NF),
which prolongs the half-life of C3 convertase from a few
seconds to 60 minutes by preventing the inhibitory action of
CFH and stabilizing C3 convertase, have been found in DDD as
well as C3GN [7]. Laser microdissection and mass spectro-
metry of glomeruli from DDD and C3GN showed the similar
proteonomic proﬁle which included the protein of AP and
terminal complement pathway [12]. Consequently, DDD and
C3GN are now regarded as different entities on the samelished by Elsevier. This is an open access article under the CC BY-NC-ND
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which is coined “C3 glomerulopathy” [13].
In brief, the new classiﬁcation of MPGN is based on the
pathogenesis of glomerular injury rather than the morphologic
ﬁndings of electron dense deposits in the previous classiﬁcation.
MPGN is newly classiﬁed into Ig-mediated MPGN showing Ig
and C3 in IF and C3 glomerulopathy with isolated C3 staining
without Ig which encompass DDD and C3GN.
In this issue, Woo et al [14], timely reclassiﬁed MPGN from
three tertiary hospitals in Korea according to the new classiﬁ-
cation. Of 46 cases of MPGN, only two cases of C3GN (4.3%)
were found and no cases of DDD were identiﬁed. Of the
remaining 44 cases of Ig-medicated MPGN, MPGN I and III
constituted 61.4% and 38.6%, respectively. Although low serum
C3 levels were found in 28% of patients, the frequency of low
serum C3 in C3GN, MPGN I, and MPGN III were not provided.
One patient with C3GN progressed to ESRD and the renal
survival was not different between MPGN I and III.
These results would stimulate further studies related to
MPGN (and consequently C3 glomerulopathy) which is by no
means a rare and benign disease. In the Progressive REnal disease
and Medical Informatics and gEnomic Research (PREMIER) study,
a biopsy registry study sponsored by the Korean Society of
Nephrology [15], MPGN accounted for 3.0% of biopsy-conﬁrmed
glomerulopathy and nephrotic syndrome was the presenting
manifestation in 32.7% of MPGN [14]. Compared with nephrotic
minimal change disease, the odd ratio of patient death and
progression to ESRD in nephrotic MPGN were 4.0 and 72.6,
respectively, in a single center study (unpublished observation).
There are several caveats in the deﬁnition of C3 glomerulo-
pathy. Although MPGN is the dominant light microscopic ﬁnding
in C3 glomerulopathy, predominant mesangial proliferative or
endocapillary proliferative features were also observed in DDD
and C3GN. In some patients with CFHR5 nephropathy, only mild
mesangial proliferation was observed in LM [16]. Thus C3
glomerulopathy incorporates MPGN and other morphological
diagnosis rather than to be a type of MPGN. On the contrary,
some cases of postinfectious glomerulonephritis showing
isolated C3 staining some time points during the clinical course
can be mistaken as C3GN but resolution of urinary abnormalities
and C3 hypocomplementemia at follow-ups would resolve this
confusion. Consequently, the integration of clinical, serological,
and pathological ﬁndings is needed to reach a correct diagnosis.
The pathological differentiation of C3 glomerulopathy from
Ig-mediated GN is not always straightforward because small
amounts of Ig could be trapped in sclerotic glomeruli or
accumulated in podocytes. The dominance of C3 staining rather
than purity of C3 staining without Ig should be diagnostic
criteria for not missing the diagnosis of C3 glomerulopathy [17].
The more perplexing ﬁnding is that either C3NF or genetic
mutation of AP proteins observed in C3 glomerulopathy were
also present in typical MPGN I. These ﬁndings might suggest
that AP dysregulation already present in patients could trigger
or exacerbate immune complex-mediated renal injury [7].
In this sense, C3 glomerulopathy can be looked upon as a
disease process by uncontrolled activation of AP, resulting in
Ig-mediated GN in some cases.
Mutation tests for genes encoding various AP proteins such
as CFH, CFHRP, CFB, and C3 and complement serological tests
seem to play an important role not only in diagnosis, but also
in choosing a speciﬁc therapeutic option targeting AP in C3
glomerulopathy. For example, replacement of deﬁcient CHF in
patients with loss of function mutation in CFH gene by plasmaexchange would be theoretically beneﬁcial. A recent expert
meeting recommended measurement of serum C3, C4, C3NF,
CFH, paraprotein, and screening for CFHR5 gene mutations in
patients with C3 glomerulopathy [18], although the feasibility
of tests, standardization of measurement methods, and inter-
pretation of test results in a given patient are barriers to be
overcome in the implementation of this recommendation.
With expanding roles of complement systems identiﬁed in
various kidney diseases such as atypical hemolytic uremic
syndrome, IgA nephropathy, membranous nephropathy, and
even in diabetic kidney disease [19] and growing lists of
therapeutic options targeting complement pathways such as
monoclonal antibody to C5a [20], soluble CR1 [21], in addition
to traditional plasmapheresis, genetic and serological tests for
complement proteins should be tested and reﬁned in patients
with previously well-deﬁned glomerular disease.
In conclusion, Woo et al [14] made a good start in C3
glomeurlopathy in Korea by reclassifying MPGN according to
new classiﬁcation systems but we have to go a long way to
assess the patients accurately in terms of genetic or acquired
defects in AP pathway causally related to glomerulopathy and
to design an appropriate therapeutic plan in individual
patients.Conﬂict of interest
The author does not have any conﬂict of interest.
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